Immune system and tumor microenvironment in early-stage breast cancer: different mechanisms for early recurrence after mastectomy and chemotherapy on ductal and lobular types
F1000Research · 2023
DOI: 10.12688/f1000research.134302.2 ↗Kurz gefasst
Fachartikel in der Zeitschrift F1000Research, 2023. Verfasst von Andreas Andrianto und 3 weiteren Autor:innen. Beteiligte Einrichtung: Doctoral Program of Medical Science, Faculty of Medicine, Universitas Airlangga, Surabaya, East Java, 60132, Indonesia. Hauptthemen laut MEDLINE: Breast Neoplasms, Carcinoma, Ductal, Breast, Carcinoma, Lobular. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
The most common type of breast cancer is the ductal type (IDC), followed by lobular type (ILC). Surgery is the main therapy for early-stage breast cancer. Adjuvant chemotherapy might be given to those at high risk of recurrence. We aimed to determine the mechanisms in early local recurrence in both types.
Methods
An observational case-controlled study was used. Early-stage IDC and ILC patients who received modified radical mastectomy (MRM) and adjuvant taxan and anthracycline base chemotherapy had recurrence within two years. We examined vimentin, α-smooth muscle actin (SMA), matrix metalloproteinase (MMP1), platelet-derived growth factor (PDGF), and clustered differentiation (CD95)
Results
In the ductal type group, there were 25 samples revealing local recurrence and 25 samples that did not recur. The lobular type group comprised six participants who did not have a recurrence, while seven subjects had a recurrence. There were significant differences in the expression of vimentin (p = 0.000 and 0.021, respectively), PDGF (p = 0.000 and 0.002), and CD95 (p = 0.000 and 0.045) in ductal and lobular cancer types, respectively. MMP1 (p = 0.000) and α-SMA (p = 0.000) only showed a significant difference in the ductal type. The pathway analysis showed that in the ductal type, the mechanism of recurrence was enabled by two factors: α-SMA and CD95. Meanwhile, for the lobular type, the recurrence mechanism was through the CD95 pathway.
Conclusions
The tumor microenvironment and immune system both affect recurrence in IDC, whereas the immune system is more important in ILC. This study suggests that immune system enhancement may be an option for treating cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Doctoral Program of Medical Science, Faculty of Medicine, Universitas Airlangga, Surabaya, East Java, 60132, Indonesia.
- Department of Pathology Anatomy, Faculty of Medicine, Universitas Airlangga, Surabaya, East Java, 60132, Indonesia.
- Division of Oncology, Department of Surgery, Faculty of Medicine, Universitas Airlangga, Surabaya, East Java, 60132, Indonesia.
- Department of Biostatistics and Population, Faculty of Public Health, Universitas Airlangga, Surabaya, East Java, 60132, Indonesia.
ORCID-Profile: Andreas Andrianto
Zitieren
APA
Andrianto, A., Sudiana, I. K., Suprabawati, D. G. A., & Notobroto, H. B. (2023). Immune system and tumor microenvironment in early-stage breast cancer: different mechanisms for early recurrence after mastectomy and chemotherapy on ductal and lobular types. F1000Research. https://doi.org/10.12688/f1000research.134302.2
Vancouver
Andrianto A, Sudiana IK, Suprabawati DGA, Notobroto HB. Immune system and tumor microenvironment in early-stage breast cancer: different mechanisms for early recurrence after mastectomy and chemotherapy on ductal and lobular types. F1000Research. 2023. doi:10.12688/f1000research.134302.2
BibTeX
@article{Andrianto2023,
author = {Andrianto, Andreas and Sudiana, I Ketut and Suprabawati, Desak Gede Agung and Notobroto, Hari Basuki},
title = {Immune system and tumor microenvironment in early-stage breast cancer: different mechanisms for early recurrence after mastectomy and chemotherapy on ductal and lobular types},
journal = {F1000Research},
year = {2023},
doi = {10.12688/f1000research.134302.2}
}
EUVIMED